Homodimeric Forms of Bombesin Act as Potent Antagonists of Bombesin on Swiss 3T3 Cells

References

• Alexander R. W., Upp J. R., Poston G. J., Gupta V., Town‐send C. M., Jr., Thompson J. C. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res 1988; 48: 1439–1441
   PubMed Web of Science ®Google Scholar
• Bepler G., Rotsch M., Jacques G., Haeder M., Heymanns J., Hartogh G., Kiefer P., Havemann K. Peptides and growth factors in small cell lung cancer: production, binding sites, and growth factors. J. Cancer Res. Clin. Oncol 1988; 114: 235–244
   PubMed Web of Science ®Google Scholar
• Bepler G., Zeymer U., Mahmoud S., Fiskum G., Palaszynski E., Rotsch M., Willey J., Koros A., Cuttitta F., Moody T. Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 1989; 9: 1367–1372
   Google Scholar
• Camble R., Cotton R., Dutta A. S., Garner A., Hayward C. F., Moore V. E., Scholes P. B. N‐isobutyryl‐His‐Trp‐Ala‐Val‐D‐Ala‐His‐Leu‐NHMe (ICI 216140) a potent in vivo antagonist analogue of bombesin/gastrin releasing peptide (BN/GRP) derived from the C‐terminal sequence lacking the final methionine residue. Life Sci 1989; 45: 1521–1527
   PubMedGoogle Scholar
• Carney D. N., Cuttitta F., Moody T. W., Minna J. D. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin‐releasing peptide. Cancer Res 1987; 47: 821–825
   PubMed Web of Science ®Google Scholar
• Coy D. H., Heinz‐Erian P., Jiang N. ‐J., Sasaki Y., Taylor J., Moreau J. P., Wolfrey W. T., Gardner J. D., Jensen R. T. Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. J. Biol. Chem 1988; 263: 5056–5060
   PubMed Web of Science ®Google Scholar
• Coy D. H., Taylor J. E., Jiang N. ‐Y., Kim S. H., Wang L. ‐H., Huang S. C., Moreau J. ‐P., Gardner J. D., Jensen R. T. Short‐chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J. Biol. Chem 1989; 264(25)14691–14697
   PubMedGoogle Scholar
• Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin‐like peptides can function as autocrine growth factors in human small cell lung cancer. Nature (London) 1985a; 316: 823–826
   PubMed Web of Science ®Google Scholar
• Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Autocrine growth factors in human small cell lung cancer. Cancer Surveys 1985b; 4(4)707–727
   PubMedGoogle Scholar
• Dower S. K., DeLisi C., Titus J. A., Segal D. M. Mechanism of binding multivalent immune complexes to Fc receptors 1. Equilibrium binding. Biochemistry 1981; 20: 6326–6334
   PubMed Web of Science ®Google Scholar
• Heimbrook D. C., Saari W. S., Balishin N. L., Friedman A., Moor K. S., Reimen M. W., Kiefer D. M., Rotberg N. S., Wallen J. W., Oliff A. Carboxyl‐terminal modification of gastrin releasing peptide derivative generates potent antagonists. 1. Biol. Chem 1989; 264: 11258–11262
   Google Scholar
• Heinz‐Erian P., Coy D. H., Tamura M., Jones S. W., Gardner J. D., Jensen R. T. ‘D‐Phe12’ bombesin analogues: A new class of bombesin receptor antagonists. Amer. J. Physiol 1987; 252: G439–G442
   PubMed Web of Science ®Google Scholar
• Heldin C. ‐H., Ernlund A., Rorsman C., Ronnstrand L. Dimerization of B‐type platelet‐derived growth factor receptors occurs after ligand binding and is closely associated with receptor kinase activation. J. Biol. Chem 1989; 264(15)8905–8912
   PubMedGoogle Scholar
• Higuchi Y., Takano Y., Simazaki H., Shimohigashi Y., Kodama H., Matsumoto H., Sakaguchi K., Nonaka S., Saito R., Waki M., Kamiya H. Dimeric substance P analogue shows a highly potent activity of the in vivo salivary secretion in the rat. Eur. J. Pharmacol 1989; 160: 413–416
   PubMedGoogle Scholar
• Jensen R. T., Heinz‐Erian P., Mantey S., Jones S. W., Gardner J. D. Characterization of ability of various substance P antagonists to inhibit action of bombesin. Am. I. Physiol 1988; 254: G883–G890
   Google Scholar
• Jensen R. T., Jones S. W., Folkers K., Gardner J. D. A synthetic peptide that is a bombesin receptor antagonist. Nature (London) 1984; 309: 61–63
   PubMed Web of Science ®Google Scholar
• Jensen R. T., Moody T., Pert C., Rivier J. E., Gardner J. D. Interaction of bombesin and litorin with specific membrane receptors on pancreatic acinar cells. Proc. Natl Acad. Sci. USA 1978; 75: 6139–6143
   PubMedGoogle Scholar
• Lackie P. M., Cuttitta F., Minna J. D., Bloom S. R., Polak J. M. Localization of receptors using a dimeric ligand and immunocytochemistry. Histochem 1985; 83: 57–59
   Google Scholar
• Laerum O. D., Sletvold O., Bjerknes R., Eriksen J. A., Johansen J. H., Schanche J. S., Tveteras T., Paukovits W. R. The dimer of hemoregulatory peptide (HP5B) stimulates mouse and human myelopoiesis in vitro. Expt. Hematol 1988; 16: 274–280
   PubMedGoogle Scholar
• McDonald T. J., Jornvall H., Nilsson G., Vagne M., Ghatei M., Bloom S. R., Mutt V. Characterization of a gastrin releasing peptide from porcine non‐antral gastric tissues. Biochem. Biophys. Res. Comm 1979; 90: 227–233
   PubMed Web of Science ®Google Scholar
• Mendoza S. A., Schneider J. A., Lopez‐Rivas A., Sinnett‐Smith J., Rozengurt E. Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells: II Changes in Na+ and Ca+ fluxes, Na+/K+ pump activity, and intracellular pH. J. Cell. Biol 1986; 102: 2223–2233
   PubMed Web of Science ®Google Scholar
• Moody T. W., Bertness V., Carney D. N. Bombesin‐like peptides and receptors in human tumor cell lines. Peptides 1983; 4: 683–686
   PubMed Web of Science ®Google Scholar
• Moody T. W., Carney D. N., Cuttitta F., Quattrocchi K., Minna J. D. High affinity receptors for bombesin/GRP‐like peptides on human small cell lung cancer. Life Sci 1985; 37: 105–113
   PubMed Web of Science ®Google Scholar
• Moody T. W., Murphy A., Mahmoud S., Fiskum G. Bombesin‐like peptides elevate cytosolic calcium in small cell cancer cells. Biochem. Biophys. Res. Comm 1987; 147(1)189–195
   PubMedGoogle Scholar
• Moody T. W., Pert C. B., Gazdar A. F., Carney D. N., Minna J. D. High levels of intracellular bombesin characterize human small cell lung carcinoma. Science 1981; 214: 1246–1247
   PubMed Web of Science ®Google Scholar
• Moody T. W., Pert C. B., Rivier J., Brown M. R. Bombesin: specific binding to rat brain membranes. Proc. Natl Acad. Sci. USA 1978; 75(11)5372–5376
   PubMedGoogle Scholar
• Rivier J. F., Brown M. R. Bombesin, bombesin analogues and related peptides: Effect on thermoregulation. Biochem 1978; 17(9)1766–1771
   PubMedGoogle Scholar
• Roth R. A., Cassell D. J., Morgan D. O., Tatnell M. A., Jones R. H., Schuttler A., Brandenburg D. Effects of covalently linked insulin dimers on receptor kinase activity and receptor down regulation. FEBS Left 1984; 170: 360–364
   PubMedGoogle Scholar
• Rozengurt E., Sinnett‐Smith J. Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc. Natl Acad. Sct. USA 1983; 80: 2936–2940
   PubMed Web of Science ®Google Scholar
• Saari W. S., Heimbrook D. C., Friedman A., Fisher T. W., Oliff A. A gastrin‐releasing peptide antagonist containing a Y(CH20) amide bond surrogate. Biochem. Biophys. Res. Comm 1989; 165: 114–117
   PubMedGoogle Scholar
• Tachè Y., Melchiorri P., Negri L. Bombesin‐like peptides in health and disease. Annals New York Acad. Sci 1988; 547
   PubMedGoogle Scholar
• Trepel J. B., Moyer J. P., Cuttitta F., Frucht H., Coy D. H., Natale R. B., Mulshine J. L., Jensen R. T., Sausville E. A. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochem. Biophys. Res. Comm 1988; 156: 1383–1389
   PubMed Web of Science ®Google Scholar
• Wang L. ‐H., Coy D. H., Taylor J. T., Jiang N. ‐Y., Kim S. H., Moreau J. ‐P., Huang S. C., Mantey S. A., Frucht H., Jensen R. T. Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochem 1990a; 29: 616–622
   PubMedGoogle Scholar
• Wang L. ‐H., Coy D. H., Taylor J. T., Jiang N. ‐Y., Moreau J. P., Huang S. C., Frucht H., Haffar B. M., Jensen R. T. Des‐met carboxy‐terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists or agonists. J. Biol. Chem 1990b; 265: 15695–15703
   PubMed Web of Science ®Google Scholar
• Weber S., Zuckerman J. E., Bostwick D. G., Bensch K. G., Sikic B. I., Raffin T. A. Gastrin‐releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J. Clin. Invest 1985; 75: 306–309
   PubMed Web of Science ®Google Scholar
• Woll P., Rozengurt E. Two classes of antagonist interact with receptors for the mitogenic neuropeptides bombesin, bradykinin and vasopressin. Growth Factors 1988; 1: 75–83
   PubMedGoogle Scholar
• Woll P. J., Rozengurt E. ‘D‐Arg1, D‐Phe5, D‐Trp7,9, Leu11’ substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc. Natl Acad. Sci. USA 1988; 85: 1859–1863
   PubMed Web of Science ®Google Scholar
• Woll P., Rozengurt E. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res 1990; 50: 3968–3973
   PubMedGoogle Scholar
• Zachary I., Rozengurt E. High‐affinity receptors for peptides of the bombesin family in Swiss 3T3 cells. Proc. Natl Acad. Sci. USA 1985; 82: 7616–7620
   PubMedGoogle Scholar